JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

JW Therapeutics announced that it has received the Investigational New Drug clearance from the National Medical Products Administration of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor T cell JWCAR129 in treating relapsed or refractory multiple myeloma.